Merck (MRK) Invested Capital (2009 - 2026)

Merck (MRK) has reported Invested Capital for 18 consecutive years, with $160.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital rose 89.4% year-over-year to $160.0 billion in Q2 2026; TTM through Jun 2026 was $160.0 billion, a 89.4% increase from a year earlier, with the FY2025 full-year figure at $164.9 billion, up 97.58% from the prior year.
• Invested Capital was $160.0 billion for Q2 2026 at Merck, up from $95.0 billion in the prior quarter.
• Over five years, Invested Capital peaked at $164.9 billion in Q4 2025 and troughed at $72.7 billion in Q4 2023.
• A 5-year average of $92.6 billion and a median of $79.5 billion in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital dropped 5.29% in 2023 and jumped 97.58% in 2025, its largest moves.
• Over 5 years, Invested Capital stood at $76.7 billion in 2022, then fell by 5.29% to $72.7 billion in 2023, then gained by 14.85% to $83.5 billion in 2024, then surged by 97.58% to $164.9 billion in 2025, then dropped by 3.01% to $160.0 billion in 2026.
• The last three Invested Capital figures came in at $160.0 billion (Q2 2026), $95.0 billion (Q1 2026), and $164.9 billion (Q4 2025), per Business Quant data.